García-Arias MR, Ramírez-García L, Matamoros-Mejía AP, Armengual-Rodríguez LA, Rivera-Salgado MI, Vicuña-González RM, Espino-Bazán A, Ramírez-Del Pilar R

Language: Spanish
References: 18
Page: 321-326
PDF size: 531.14 Kb.

ABSTRACT

Castleman’s disease is a heterogeneous group of lymphoproliferative disorders (LPD’S), which has two types of presentation, unicentric (UCD) and multicentric (MCD) variety. Histologically it is characterized by lymph nodes with hyperplasia of germinal centers and increased vascularity. This article reports the clinical case of a 70-year-old female with previous autologous haematopoietic stem cell transplant. She arrived with asthenia, weight loss, abdominal pain and progressive dyspnea. A retroperitoneal tumor and right pleural effusion were found. Clinical approach and bibliographic review are reported, the incidence estimation for this disorder is 21-25 cases per million population, and only 14% of reported cases had a retroperitoneal presentation.

REFERENCES

1. Castleman, B, Ikerson l, Menendez VP. Localized mediastinal lymph node hyperplasia. Cancer 1956;9(5):822-830.

2. Said, J. Multicentric Castleman disease: consensus at last? Blood 2017;129(12):1569-1570.

3. Spencer TD, Maier RV, Olson HH. Retroperitoneal giant lymph node hyperplasia A case report and review of the literature. Am Surg 1984;50(9):509-514.

4. Kinjal, V. A case of Castleman’s disease that presented as a retroperitoneal mass. Nat Clin Pract Urol 2007;4(5).

5. Munshi N. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015;56(5):1252-1260.

6. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph-node hyperplasia of the mediastinum and other locations. Cancer 1972;29(3):670-683.

7. Yalcin A, Avci A. Castleman’s Disease. Internet J Hematol 2007;4(2):1-6.

8. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3(9):1202-1216.

9. Mccarty MJ, Vukelja SJ, Banks PM, Weiss RB. Angiofollicular lymph node hyperplasia (Castleman’s disease). Cancer Treat Rev 1995;21(4):291-310.

10. Li Y, Meifeng T, Cortes J, Zijun Y. Clinical and pathological characteristics of HIV-and HHV8- negative Castleman disease. Blood 2017;129(12):1658-1668.

11. Chan HKL, Prince HM, Harrison SJ. Update and new approaches in the treatment of Castleman disease. Blood Med 2016;3(7):145-158.

12. Escrivá AA, Gómez J, Munárriz B. Trastornos linfoproliferativos postraplante. Med Clin 1998;111(1):32-26.

13. Frazier AA. Unicentric versus multicentric Castleman disease. Radiographics 2016;36(5):1308.

14. Frizzera G. Castleman’s disease and related disorders. Semin Diagn Pathol 1988;5(4):346-364.

15. Fajgenbaum D, Uldrick TS, Bagg A, Frank D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/ idiopathic multicentric Castleman disease. Blood 2017;129(12):1646-1657.

16. Zapata SA, López R, Scherling AA. Enfermedad de Castleman multicéntrica tipo hialino-vascular en paciente inmunocompetente. Gac Med Mex 2015;151(1):648- 654.

17. Hao-wei W, Pittaluga S, Jaffe ES. Multicentric Castleman disease: Where are we now? Semin Diagn Pathol 2016;33(5):293-306.

18. Nishimoto N, Kanakura Y, Aozasa Z. Humanized antiinterleukin- 6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106(8):2627-2632.